Literature DB >> 18759848

A latent contingency table approach to dose finding for combinations of two agents.

Guosheng Yin1, Ying Yuan.   

Abstract

Two-agent combination trials have recently attracted enormous attention in oncology research. There are several strong motivations for combining different agents in a treatment: to induce the synergistic treatment effect, to increase the dose intensity with nonoverlapping toxicities, and to target different tumor cell susceptibilities. To accommodate this growing trend in clinical trials, we propose a Bayesian adaptive design for dose finding based on latent 2 x 2 tables. In the search for the maximum tolerated dose combination, we continuously update the posterior estimates for the unknown parameters associated with marginal probabilities and the correlation parameter based on the data from successive patients. By reordering the dose toxicity probabilities in the two-dimensional space, we assign each coming cohort of patients to the most appropriate dose combination. We conduct extensive simulation studies to examine the operating characteristics of the proposed method under various practical scenarios. Finally, we illustrate our dose-finding procedure with a clinical trial of agent combinations at M. D. Anderson Cancer Center.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759848     DOI: 10.1111/j.1541-0420.2008.01119.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  28 in total

Review 1.  Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Authors:  Christophe Le Tourneau; Véronique Diéras; Patricia Tresca; Wulfran Cacheux; Xavier Paoletti
Journal:  Target Oncol       Date:  2010-04-02       Impact factor: 4.493

2.  Adaptive clinical trial designs in oncology.

Authors:  Yong Zang; J Jack Lee
Journal:  Chin Clin Oncol       Date:  2014-12

3.  A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.

Authors:  Akihiro Hirakawa; Nolan A Wages; Hiroyuki Sato; Shigeyuki Matsui
Journal:  Stat Med       Date:  2015-05-13       Impact factor: 2.373

4.  A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities.

Authors:  Suyu Liu; Jing Ning
Journal:  Bayesian Anal       Date:  2013-09-09       Impact factor: 3.728

5.  A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy.

Authors:  Wei Zhong; Joseph S Koopmeiners; Bradley P Carlin
Journal:  Stat Med       Date:  2012-07-16       Impact factor: 2.373

6.  The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM.

Authors:  Joseph S Koopmeiners; Andrew Wey
Journal:  J Biopharm Stat       Date:  2017-03-25       Impact factor: 1.051

7.  A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.

Authors:  Liangcai Zhang; Ying Yuan
Journal:  Stat Med       Date:  2016-08-31       Impact factor: 2.373

Review 8.  Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority.

Authors:  Ying Yuan; J Jack Lee; Susan G Hilsenbeck
Journal:  JCO Precis Oncol       Date:  2019-10-24

9.  Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.

Authors:  Márcio Augusto Diniz; Mourad Tighiouart
Journal:  J Biom Biostat       Date:  2017-11-27

10.  A Generalized Continual Reassessment Method for Two-Agent Phase I Trials.

Authors:  Thomas M Braun; Nan Jia
Journal:  Stat Biopharm Res       Date:  2013-01-01       Impact factor: 1.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.